Skip to main content
An official website of the United States government
Government Funding Lapse
Because of a lapse in government funding, the information on this website may not be up to date, transactions submitted via the website may not be processed, and the agency may not be able to respond to inquiries until appropriations are enacted.

The NIH Clinical Center (the research hospital of NIH) is open. For more details about its operating status, please visit cc.nih.gov.

Updates regarding government operating status and resumption of normal operations can be found at opm.gov.

rituximab

View Patient Information
A recombinant chimeric murine/human antibody directed against the CD20 antigen, a hydrophobic transmembrane protein located on normal pre-B and mature B lymphocytes. Following binding, rituximab triggers a host cytotoxic immune response against CD20-positive cells.
Check for active clinical trials using this agentView this agent in the NCI Thesaurus
Synonym:C2B8 monoclonal antibody
chimeric anti-CD20 antibody
IDEC-C2B8 monoclonal antibody
monoclonal antibody IDEC-C2B8
rituximab ABBS
rituximab ARRX
rituximab biosimilar ABP 798
rituximab biosimilar BI 695500
rituximab biosimilar CT-P10
rituximab biosimilar GB241
rituximab biosimilar IBI301
rituximab biosimilar PF-05280586
rituximab biosimilar RTXM83
rituximab biosimilar SAIT101
rituximab biosimilar SIBP-02
rituximab biosimilar TQB2303
rituximab PVVR
rituximab-abbs
rituximab-arrx
rituximab-pvvr
US brand name:Riabni
Rituxan
Ruxience
Truxima
Foreign brand name:Ikgdar
Mabtas
MabThera
Code name:ABP 798
BI 695500
CT-P10
IDEC-102
IDEC-C2B8
PF-05280586
rituximab biosimilar JHL1101
RTXM83
Search NCI's Drug Dictionary
Please enter up to 30 characters for your search